因塞特醫療 INCY 深 滬
等待開盤 03-26 09:30:00 美东时间
92.23
+1.610
+1.78%
華盛通- 最 高93.83
- 今 開91.00
- 成交量 105.57万股
- 最 低 91.00
- 昨 收 90.62
- 總市值 183.54亿
- 52周最高 112.29
- 市盈率 靜 14.39
- 換手率 0.53%
- 52周最低 53.56
- 委 比 51.78%
- 總股本 1.99亿
- 歷史最高 153.15
- 量 比 0.51
- 振 幅 3.12%
- 歷史最低 11.76
- 每 手 1
- 風險率 16.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
今天 11:41
UBS Maintains Neutral on Incyte, Lowers Price Target to $94
UBS analyst Ashwani Verma maintains Incyte (NASDAQ:INCY) with a Neutral and lowers the price target from $104 to $94.
今天 00:03
BRIEF-Incyte Announces Executive Leadership Appointments
BRIEF-Incyte Announces Executive Leadership Appointments Incyte Corp INCY.O : INCYTE ANNOUNCES EXECUTIVE LEADERSHIP APPOINTMENTS Source text: ID:nBw2vymNna Further company coverage: INCY.O
03-25 21:01
UPDATE 2-Karyopharm's drug reduces spleen size in rare blood cancer study
UPDATE 2-Karyopharm's drug reduces spleen size in rare blood cancer study Adds shares in paragraph 2, details throughout March 24 (Reuters) - Karyopharm Therapeutics KPTI.O said on Tuesday its therapy for patients with a rare blood cancer showed a reduction in spleen size in a late-stage trial, meet
03-24 19:26
Knight Therapeutics Secures ANVISA Nod For MINJUVI In Brazil Under Distribution Pact With Incyte
Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian
03-17 19:39
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Jefferies Downgrades Incyte to Hold, Lowers Price Target to $94
Jefferies analyst Faisal Khurshid downgrades Incyte (NASDAQ:INCY) from Buy to Hold and lowers the price target from $120 to $94.
03-16 20:47
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monda
03-16 18:00
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
MacroGenics updates its corporate progress, financial results for 2025, and 2026 milestones. Key highlights include Phase 1 results for MGC026 and MGC028 expected in mid-2026 and late 2026, respectively, and IND submission for MGC030 planned for Q3 2026. The company reported $189.9 million in cash as of December 31, 2025, with cash runway extending into late 2027. Additionally, updates on partnerships with Gilead, Sanofi, and Incyte, as well as L...
03-09 20:01
